These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33941739)

  • 1. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
    Drennan PG; Thoma Y; Barry L; Matthey J; Sivam S; van Hal SJ
    Ther Drug Monit; 2021 Aug; 43(4):505-511. PubMed ID: 33941739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care.
    Brockmeyer JM; Wise RT; Burgener EB; Milla C; Frymoyer A
    Pediatr Pulmonol; 2020 Dec; 55(12):3343-3350. PubMed ID: 32827334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
    Barras MA; Serisier D; Hennig S; Jess K; Norris RL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
    Gao Y; Hennig S; Barras M
    Clin Pharmacokinet; 2019 Mar; 58(3):389-399. PubMed ID: 30140975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.
    Praet A; Bourguignon L; Vetele F; Breant V; Genestet C; Dumitrescu O; Doleans-Jordheim A; Reix P; Goutelle S
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073721. PubMed ID: 34280011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
    Burgard M; Sandaradura I; van Hal SJ; Stacey S; Hennig S
    Clin Pharmacokinet; 2018 Aug; 57(8):1017-1027. PubMed ID: 29134570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis.
    Sherwin CM; Zobell JT; Stockmann C; McCrory BE; Wisdom M; Young DC; Olson J; Ampofo K; Spigarelli MG
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):71-9. PubMed ID: 24395072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation.
    Downes KJ; Grim A; Shanley L; Rubenstein RC; Zuppa AF; Gastonguay MR
    Antimicrob Agents Chemother; 2022 May; 66(5):e0237721. PubMed ID: 35481751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
    de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
    Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
    Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
    Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
    Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
    J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
    Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
    J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
    Brigg Turner R; Elbarbry F; Biondo L
    J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.